Sponsors

Lead Sponsor

Emory University

Collaborators

National Cancer Institute (NCI)
National Institutes of Health (NIH)

PRIMARY OBJECTIVE: I. Assess the effects on quality of life (QOL) when supplementing zinc in upper gastrointestinal (GI) cancer patients while they are receiving chemotherapy. SECONDARY OBJECTIVES: I. Correlate hypoalbuminemia with serum zinc deficiency. II. Correlate zinc deficiency with neutropenia. OUTLINE: Patients are randomized into 1 of 2 groups. GROUP I: Patients receive zinc orally (PO) thrice daily (TID) for months 1 and 2 only of the first 4 months on therapy. GROUP II: Patients receive zinc orally (PO) TID for months 3 and 4 only of the first 4 months on therapy.

Related studies

RECRUITINGPhase 2

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

NCT05969860 · Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma, and more

RECRUITINGPhase 1

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

NCT04704661 · Advanced Breast Carcinoma, Advanced Colon Carcinoma, and more

RECRUITINGPhase 2

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

NCT04550494 · Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, and more

RECRUITINGNA

Risk Assessment Evaluation for Identifying Participants at High Risk for Stomach Cancer

NCT06408220 · Gastric Carcinoma

RECRUITING

Analysis of Tumor Deposit at the Fusion Site of the Right Gastric Mesentery and Left Gastric Mesentery in the Patients With Gastric Cancer Who Received Proximal Gastrectomy

NCT06728891 · Gastric Carcinoma

View all related studies →

Effects on Quality of Life With Zinc Supplementation in Patients With Gastrointestinal Cancer

What this study is about

Clareo turns complex medical information into clear understanding you can use.

Sponsors

Related studies

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Risk Assessment Evaluation for Identifying Participants at High Risk for Stomach Cancer

Analysis of Tumor Deposit at the Fusion Site of the Right Gastric Mesentery and Left Gastric Mesentery in the Patients With Gastric Cancer Who Received Proximal Gastrectomy

Trial snapshot

Condition

Locations shown

For caregivers